Analysts at Bank of America/Merrill (BAC) upgraded Sarepta Therapeutics, Inc. (SRPT) from ‘Neutral’ to ‘Buy’ in a research report issued to clients on Tuesday. The firm says it has increased confidence that Eteplirsen will be approved for treating boys with Duchenne muscular dystrophy. The target price for SRPT is raised to $21 from $19.
On valuation measures, Sarepta Therapeutics stock has five year expected PEG ratio of 20.35 and a trailing-12 price/sales of 42.66.
The T-twelve-month revenue at Sarepta Therapeutics Inc. is $12.36M. SRPT ‘s ROE for the same period is -37.58%.
Shares of the $600.63M market cap company are down 52.03% year-over-year, and 11.82% year-to-date.
SRPT, currently with a median Wall Street price target of $22.00 and a high target of $52.00, rose $1.78 to $14.54 in recent trading.
The chart below shows where the equity has traded over the past 52-weeks.
FireEye, Inc. (FEYE) was reiterated a ‘Buy’ by BofA/Merrill (BAC) analysts on Tuesday. The broker also increased to $49 from $44 its price target on the stock.
The move comes on a big volume too with the issue currently trading more than 10.6 million shares, well ahead of its three month daily average of 6 million shares.
Shares of FireEye Inc have traded today between $42.00 and $44.37 with the price of the stock fluctuating between $24.81 to $97.35 over the last 52 weeks.
On valuation measures. ticker has a t-12 price/sales ratio of 14.67. EPS for the same period registers at ($3.12).
Shares of FEYE have gained $1.97 to $44.23 in mid-day trading on Tuesday, giving it a market cap of roughly $6.53B. The stock traded as high as $97.35 in Mar 5, 2014.
Investment analysts at Northland Capital initiated coverage on shares of GoPro, Inc. (GPRO) in a note issued to investors on Tuesday. The firm set an ‘Outperform’ rating and a $70.00 price target on the stock. The firm’s price target would suggest a potential upside of 40.64% from the name’s current price of $49.62.
GoPro, Inc. shares are currently priced at 54.03x this year’s forecasted earnings compared to the industry’s 11.42x earnings multiple. Ticker has a PEG and forward P/E ratio of 1.25 and 29.32, respectively. Price/Sales for the same period is 4.12 while EPS is $0.92. Currently there are 4 analysts that rate GPRO a ‘Buy’, 10 rate it a ‘Hold’. 1 analyst rates it a ‘Sell’. GPRO has a median Wall Street price target of $61.00 with a high target of $105.00.
Shares are down 28.39% year-to-date, and have traded between a low of $28.65 and a high of $98.47.
Micron Technology, Inc.’s (MU) rating of ‘Buy’ was reiterated today at Jefferies with a price target increase to $45 from $42 (versus a $31.85 close).
Micron Technology shares have surged 29.17% over the past 52 weeks, while the S&P 500 index has gained 13.92% in the same period.
Micron recently traded at $32.41, up 1.76 percent.